VIDEO: What patients are saying about long-acting cabotegravir for HIV PrEP
Click Here to Manage Email Alerts
LOS ANGELES —In this video from IDWeek, Vani Vannappagari, MBBS, PhD, MPH, global head of epidemiology and real-world evidence at ViiV Healthcare, discusses study findings demonstrating the effectiveness of cabotegravir for HIV prevention.
The FDA approved cabotegravir in 2021 as the first long-acting injectable for PrEP after it outperformed oral medication in studies.
Cabotegravir is administered every 2 months. Another long-acting injectable, lenacapavir, is given every 6 months and has demonstrated close to 100% efficacy against HIV acquisition in trials.
Real-world data from two trials, OPERA and TRIO, showed that cabotegravir was more than 99% effective at preventing HIV among more than 1,200 combined participants, according to findings presented at IDWeek.
In the video, Vannappagari talks more about the people enrolled in the two trials and what they are saying about cabotegravir.
“They report a very low level of anxiety and stigma and a high level of acceptance,” she said.
References:
- Mills AM, et al. Abstract 508. Presented at: IDWeek; Oct. 16-19, 2024; Los Angeles.
- Ramgopal M, et al. Abstract 505. Presented at: IDWeek; Oct. 16-19, 2024; Los Angeles.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts